Wyva
Senior Member (Voting Rights)
Two abstracts from the 32nd International Congress of Clinical Neurophysiology (ICCN) of the IFCN, September 4-8, 2022, Geneva, Switzerland.
The authors are neurologists at the National Institute of Mental Health, Neurology, and Neurosurgery, Budapest.
TH-284. Dysautonomia in patients recovered from COVID-19, 2022, Győrfi et al
TH-285. Autonomic nervous system dysfunction in long-COVID patients, 2022, Győrfi et al
Edit: I've just realized these are from 2022, not this year, so edited the years accordingly.
The authors are neurologists at the National Institute of Mental Health, Neurology, and Neurosurgery, Budapest.
TH-284. Dysautonomia in patients recovered from COVID-19, 2022, Győrfi et al
Introduction: Following acute COVID–19 infection several persistent symptoms (sweating dysfunctions, palpitations, orthostatic intolerance) might be related to immune-mediated disruption of the autonomic nervous system. We present the results of small fiber examination in patients with post-COVID syndrome.
Methods: In our database, we enrolled 32 patients who recovered from COVID-19. After recording the demographic data and post-COVID symptoms, the participants completed the Composite Autonomic Symptom Scale – 31 (COMPASS-31) questionnaire, followed by a complete neurological examination. Sudomotor function was assessed using the Vitalscan Sudocheck machine, while the cardiac function was recorded with Wiwe device.
Results: Dizziness, fatigue, “brain fog,” palpitations, and numbness were the most common symptoms. None of the patients presented any focal signs on neurological examination. The participants were classified into four groups based on neurophysiological findings: patients in group A (n=8, 25%) showed impaired sympathetic skin response, defined as bioelectrical conductivity < 60 µS. Decreased quantitative sudomotor axon reflex test, established as low sweat activity reflex was noted in 5 (16%) patients (group B). Group C (n=14, 44%) consisted of cases with impaired heart rate variability, established as a reduction in any of the time domain indices (SDNN, PNN50, and RMSSD). Group D included 7 (22%) post-COVID patients, who did not present any functional abnormality on the above-mentioned neurophysiological modalities.
Despite the small sample size, group B showed the highest COMPASS-31 total score (12.5/100) compared to the other groups (group A: 9/100, group B:10/100). Among all the cases, group B patients presented the highest scores in COMPASS-31 pupillomotor subdomain assessment (4/12).
Group A presented lower SDNN and RMSSD indices compared to patients without sudomotor dysfunction (only the RMSSD data showed a statistically significant difference; p< 0,05). Despite our expectations, the scores of the COMPASS-31 secretomotor subdomain in Group A did not show any significant difference compared to the other groups. Examining the COMPASS-31 subdomains in neurophysiologically intact cases in group D, we found that the highest scores pertain to the gastrointestinal subdomain.
Conclusion: Dysautonomia is becoming more widely evident as a chronic consequence of COVID infection. The COMPASS-31 questionnaire showed a sensitivity of 100% and a positive predictive value of 80%, but we noticed several inconsistencies. The discrepancy between the sub-scores of the small fiber questionnaire and the results of the neuropsychological examination address the need for further extended autonomic studies.
TH-285. Autonomic nervous system dysfunction in long-COVID patients, 2022, Győrfi et al
Introduction: Accumulating evidence supports that 6 months after COVID-19 almost 80% of the patients present residual neurological manifestations. Some of these symptoms may be associated with autonomic nervous system (ANS) damage. Several possible mechanisms have been proposed, including the detrimental effect of the virus-induced cytokine storm, direct viral spread into the nervous system, and an immune-mediated autoimmune mechanism. The extent of ANS involvement and exact pathological locations are unknown.
Methods: The aim of our study was to characterize the peripheral autonomic nervous system involvement in post-COVID patients. We compared the outcomes of neurological and neurophysiological examinations with the results of asymptomatic control subjects.
In our study, we studied 33 patients (20 women, mean age: 39 ± 8 years) with post-COVID, transient or persistent neurocognitive and/or autonomic nervous system symptoms and 8 (4 women, 29 ± 5 years) control subjects. After detailed neurological examination, the ANS functional assessment was performed with Quantitative Sudomotor Axon Reflex Test (QSART) and Sudomotor Sympathetic Skin Response (SSR) using Vitalscan SudoCheck + machine. Heart rate variability (HRV) was determined using a WIWE instrument.
Results: Focal neurological signs were not found in any of the patients. Regarding the autonomic nervous system studies, SSR measurement was the most sensitive in our population: we found abnormal SSR values in 8/33 of our post-COVID patient group (24%), while we did not find any abnormal SSR values in the control group. These 8 post-COVID patients showed moderate to severe (bioelectrical skin conductivity: 24.3-59.4 µS) ANS dysfunction. During the one-minute HRV measurement, we assessed the standard deviation of heart rate variability (SDNN) and the root mean square of the RR intervals (RMSSD). Abnormally low values were measured in 14/33 patients (42%) (SDNN mean: 18-23 ms, RMSSD mean: 13-14 ms).
Conclusion: In our study, different neurophysiological examination modalities confirmed ANS involvement in post-COVID patients. The extent of cardiovascular autonomic involvement (42%) was higher than sudomotor dysfunction (24%). These ratios significantly exceed the results of similar measurements in the age-matched control group. We suggest that the dysautonomia profile might explain the persistent symptoms after COVID-19.
Edit: I've just realized these are from 2022, not this year, so edited the years accordingly.
Last edited: